Enteropathy-associated T-cell lymphoma

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 1, 2011, Pages 84-90

  Ferreri, Andrés J M ^a   Zinzani, Pier Luigi ^b   Govi, Silvia ^a   Pileri, Stefano A ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Coeliac disease; Intestinal lymphoma; Malabsorption; T cell lymphoma

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; CARMUSTINE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; DRUG MEGADOSE; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; MULTIPLE CYCLE TREATMENT; PROGNOSIS; REVIEW; T LYMPHOCYTE SUBPOPULATION; TREATMENT INDICATION;

ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA; HUMANS;

EID: 79957938142     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.06.006     Document Type: Review

References (58)

1. Daum S., Foss H.D., Anagnostopoulos I., et al. Expression of cytotoxic molecules in intestinal T-cell lymphomas. The German study group on intestinal non-hodgkin lymphoma. J Pathol 1997, 182:311-317.
2. Catassi C., Bearzi I., Holmes G.K. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005, 128:S79-S86.
3. Card T.R., West J., Holmes G.K. Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study. Aliment Pharmacol Ther 2004, 20:769-775.
4. Ilyas M., Niedobitek G., Agathanggelou A., et al. Non-Hodgkin's lymphoma, coeliac disease, and Epstein-Barr virus: a study of 13 cases of enteropathy-associated T- and B-cell lymphoma. J Pathol 1995, 177:115-122.
5. Wright D.H. The major complications of coeliac disease. Baillieres Clin Gastroenterol 1995, 9:351-369.
6. Bagdi E., Diss T.C., Munson P., Isaacson P.G. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood 1999, 94:260-264.
7. Ashton-Key M., Diss T.C., Pan L., Du M.Q., Isaacson P.G. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am J Pathol 1997, 151:493-498.
8. Cellier C., Delabesse E., Helmer C., et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French coeliac disease study group. Lancet 2000, 356:203-208.
9. Cellier C., Patey N., Mauvieux L., et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998, 114:471-481.
10. Daum S., Cellier C., Mulder C.J. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005, 19:413-424.
11. Verkarre V., Romana S.P., Cellier C., et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 2003, 125:40-46.
12. Thomas J.A., Allday M.J., Crawford D.H. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv Cancer Res 1991, 57:329-380.
13. Penn I. Cancers following cyclosporine therapy. Transplantation 1987, 43:32-35.
14. Domizio P., Owen R.A., Shepherd N.A., Talbot I.C., Norton A.J. Primary lymphoma of the small intestine. A clinicopathological study of 119 cases. Am J Surg Pathol 1993, 17:429-442.
15. Quintanilla-Martinez L., Lome-Maldonado C., Ott G., et al. Primary non-Hodgkin's lymphoma of the intestine: high prevalence of Epstein-Barr virus in Mexican lymphomas as compared with European cases. Blood 1997, 89:644-651.
16. Isaacson P.G., Norton A.J. Extranodal lymphomas 1994, Churchill Livingstone, Edinburgh, Scotland. 1st ed.
17. Wright D.H. Enteropathy associated T cell lymphoma. Cancer Surv 1997, 30:249-261.
18. Chott A., Haedicke W., Mosberger I., et al. Most CD56+ intestinal lymphomas are CD8+CD5- T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998, 153:1483-1490.
19. Howell W.M., Leung S.T., Jones D.B., et al. HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Hum Immunol 1995, 43:29-37.
20. Deleeuw R.J., Zettl A., Klinker E., et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007, 132:1902-1911.
21. Zettl A., Ott G., Makulik A., et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol 2002, 161:1635-1645.
22. Zettl A., Rudiger T., Muller-Hermelink H.K. Enteropathy type T-cell lymphomas: pathology and pathogenesis. Pathologe 2007, 28:59-64.
23. Levine M.S., Rubesin S.E., Pantongrag-Brown L., Buck J.L., Herlinger H. Non-Hodgkin's lymphoma of the gastrointestinal tract: radiographic findings. AJR Am J Roentgenol 1997, 168:165-172.
24. Hovenga S., de G.H., Joosten P., et al. Enteropathy-associated T-cell lymphoma presenting with eosinophilia. Neth J Med 2003, 61:25-27.
25. Gobbi C., Buess M., Probst A., et al. Enteropathy-associated T-cell lymphoma with initial manifestation in the CNS. Neurology 2003, 60:1718-1719.
26. Hadithi M., Mallant M., Oudejans J., et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 2006, 47:1622-1627.
27. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971, 31:1860-1861.
28. Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas (author's transl). Strahlentherapie 1977, 153:218-221.
29. Blackledge G., Bush H., Dodge O.G., Crowther D. A study of gastro-intestinal lymphoma. Clin Oncol 1979, 5:209-219.
30. Rohatiner A., d'Amore F., Coiffier B., et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994, 5:397-400.
31. Gale J., Simmonds P.D., Mead G.M., Sweetenham J.W., Wright D.H. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000, 18:795-803.
32. Chott A., Dragosics B., Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol 1992, 141:1361-1371.
33. d'Amore F., Brincker H., Gronbaek K., et al. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol 1994, 12:1673-1684.
34. Liang R., Chiu E., Chan T.K., Todd D., Loke S.L. Direct comparison of peripheral T-cell lymphomas with their B-cell counterpart. Acta Haematol 1991, 85:179-183.
35. Morton J.E., Leyland M.J., Vaughan H.G., et al. Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases. Br J Cancer 1993, 67:776-782.
36. Novakovic B.J., Novakovic S., Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep 2006, 16:191-195.
37. Honemann D., Prince H.M., Hicks R.J., Seymour J.F. Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Ann Hematol 2005, 84:118-121.
38. Daum S., Ullrich R., Heise W., et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol 2003, 21:2740-2746.
39. Stewart A.K., Shepherd F.A., Goss P.E., et al. Gastrointestinal non-Hodgkin's lymphoma. Leuk Lymphoma 1991, 4:167-176.
40. Zinzani P.L., Magagnoli M., Pagliani G., et al. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica 1997, 82:305-308.
41. Shih L.Y., Liaw S.J., Dunn P., Kuo T.T. Primary small-intestinal lymphomas in Taiwan: immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease. J Clin Oncol 1994, 12:1375-1382.
42. Okuda M., Nomura J., Tateno H., Kameoka J., Sasaki T. CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation. Intern Med 2002, 41:734-737.
43. Al-Toma A., Verbeek W.H., Visser O.J., et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis 2007, 39:634-641.
44. Rongey C., Micallef I., Smyrk T., Murray J. Successful treatment of enteropathy-associated T cell lymphoma with autologous stem cell transplant. Dig Dis Sci 2006, 51:1082-1086.
45. Bishton M.J., Haynes A.P. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 2007, 136:111-113.
46. d'Amore F., Relander T., Lauritzen G.F., et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLS)-overall and subtype-specific results of a phase II study from the Nordic Lymphoma Group. Haematologica 2009, 94(Suppl. 2):437.
47. Sieniawski M., Angamuthu N., Boyd K., et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010, 115:3664-3670.
48. Meijer J.W., Mulder C.J., Goerres M.G., Boot H., Schweizer J.J. Coeliac disease and (extra)intestinal T-cell lymphomas: definition, diagnosis and treatment. Scand J Gastroenterol Suppl 2004, 78-84.
49. Al-Toma A., Visser O.J., van Roessel H.M., et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007, 109:2243-2249.
50. Ravandi F., Aribi A., O'Brien S., et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009, 27:5425-5430.
51. Gallamini A., Zaja F., Patti C., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316-2323.
52. Kim J.G., Sohn S.K., Chae Y.S., et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007, 60:129-134.
53. Soldini D., Mora O., Cavalli F., Zucca E., Mazzucchelli L. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma. Br J Haematol 2008, 142:484-486.
54. Vivas S., Ruiz de Morales J.M., Ramos F., Suarez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 2006, 354:2514-2515.
55. Al-Toma A., Mulder C.J. Review article: stem cell transplantation for the treatment of gastrointestinal diseases-current applications and future perspectives. Aliment Pharmacol Ther 2007, 26(Suppl. 2):77-89.
56. Jaffe E.S., Krenacs L., Kumar S., Kingma D.W., Raffeld M. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 1999, 111:S46-S55.
57. Crump M., Gospodarowicz M., Shepherd F.A. Lymphoma of the gastrointestinal tract. Semin Oncol 1999, 26:324-337.
58. Kim S.J., Kim K., Kim B.S., et al. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol 2009, 20:390-392.